Accropeutics Inc.

Accropeutics Inc. is a biotechnology company specializing in innovative therapeutic solutions that target regulated cell death mechanisms to treat immune-mediated diseases. Accropeutics Inc. , founded in 2017, is based in Suzhou, China.

The company is focused on the development of therapeutics addressing immune-mediated diseases. In March 2025, Accropeutics raised USD 12 mn in Series B funding led by Shenzhen Capital Group, alongside other investors. The company has completed a total of 2 deals to date, with the latest being on March 14, 2025. The founder, whose specific background is not detailed, has previously been involved in the biotechnology sector with no mention of other companies founded.

Accro Bioscience (Suzhou) Limited develops innovative therapeutics focused on mechanisms of regulated cell death to combat immune-mediated diseases. Its lead products include AC-101, a RIPK2 inhibitor for moderate-to-severe Ulcerative Colitis, and AC-201, a TYK2/JAK1 inhibitor for non-infectious uveitis and moderate-to-severe plaque psoriasis, currently in clinical trials across multiple regions including China and potentially the United States. Accro Bioscience's revenue primarily arises from partnerships and funding for clinical trials, typical of the biotechnology sector. Collaborations with healthcare institutions support the clinical development of AC-101 and AC-201.

Revenue generation will also depend on milestones achieved during trials and future commercialization agreements with pharmaceutical companies as products gain regulatory approval. Accropeutics Inc. aims to enhance its operations and business reach through the recent funding of USD 12 mn, raised in March 2025. The company plans to expand into new geographical markets, particularly targeting the United States, while continuing to progress its product pipeline.

New products are in development, with strategic initiatives to be supported by the recent Series B funding.